RCS - NLS Pharmaceutics AG - NLS Pharmaceutics Announces an R&D Update Webcast

NLS Pharmaceutics AGAnnouncement

12/01/2023 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230112:nRSL5779Ma&default-theme=true

RNS Number : 5779M  NLS Pharmaceutics AG  12 January 2023

NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's
Growing Portfolio of Pre-Clinical Compounds

·      Management to Discuss Pipeline Goals and Development Strategies
across four Preclinical and 2 Clinical Programs across Multiple Central
Nervous System (CNS) Disorders

·      NLS to Webcast its R&D Day Event Tuesday, January 31 at 10:00am
EST

ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2023 / NLS Pharmaceutics Ltd.
(Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage
biopharmaceutical company focused on the discovery and development of
innovative therapies for patients with rare and complex central nervous system
disorders, today announced plans to showcase its global strategic R&D
progress and platform, as well as its product candidate and pipeline goals for
2023, with a focus on rare and complex CNS disorders with unmet medical needs.
NLS will webcast its upcoming virtual R&D Day event on the Investors
section of the Company's website, www.nlspharma.com, on January 31, 2023, at
10:00 am EST.

Highlights of NLS' Pipeline

NLS-13 (mazindol)

Target indication: Idiopathic hypersomnia (IH)

·      Orphan Drug Designation in the U.S. and Europe

·      Phase 2 studies with Mazindol ER demonstrated efficacy in
narcolepsy patients with Type II disorder, which has strong similarities to IH

·      Promising results support continued development of NLS-13
(mazindol) for IH

·      No approved treatment in Europe, 1 approved therapy in the U.S.

·      Early access program under named-patient program has been
initiated in Europe with the potential to generate short-term, non-dilutive
revenues for NLSP

NLS-3 (phacetoperane)

Target: Attention deficit hyperactivity disorder (ADHD)

·      Preclinical studies for NLS-3 (phacetoperane) show potential for
the treatment of ADHD with improved efficacy, safety and tolerability versus
methylphenidate

·      Promising results support continued development of NLS-3
(phacetoperane)

·      NLS has intellectual property (IP) patent protections for NLS-3
in the U.S., Japan, China and Europe.

NLS-4 (lauflumide)

Target indication: Chronic fatigue syndrome (CFS) associated with long COVID
and cancer patients

·      Preclinical studies for NLS-4 (lauflumide) show potential for the
treatment of chronic fatigue associated with Long-COVID (AKA "Chronic Fatigue
caused be COVID-19 infection") and demonstrated improved recovery from CFS) in
rat model

·      Promising results support continued development of NLS-4
(lauflumide)

·      NLS has intellectual property (IP) patent protections for NLS-4
in the U.S., Canada and Europe

NLS-8 (melafenoxate)

Target indication: Amnesia associated with Alzheimer's

·      Preclinical study for NLS-8 (melafenoxate) focusing on
neurodegenerative disorders, specifically on the pathological process of
Alzheimer's Disease (AD) demonstrated an improvement on amnesia symptoms
associated with neurodegenerative disorders, specifically AD, in mice model

·      Promising results support continued development of NLS-8
(melafenoxate) to improve memory and reduce cognitive symptoms of AD

·      The European Patent Office has granted approval for International
Patent Application No. PCT/EP2022/069204 including the NLS-11 mechanism of
action and its applications as neurological diseases treatment associated with
sleep disorders

NLS-11 (benedin)

Target indication: Kleine-Levin Syndrome

·      Preclinical development of NLS-11 (benedin), an innovative drug
targeting the Kleine-Levin Syndrome (KLS), demonstrated a clinical benefit on
hypersomnia symptoms and exhaustion associated with KLS in mice models. As of
today, there are no approved treatment available world-wide to cure or control
KLS

·      Promising results in addition to extensive historical preclinical
data, as well as preliminary clinical data, support continued development of
NLS-11 (benedin) in KLS and other rare sleep disorders

·      The European Patent Office has granted approval for International
Patent Application No. PCT/EP2022/069188 including the NLS-11 mechanism of
action and its applications as neurological diseases treatment associated with
sleep disorders

NLS-12 (oxafuramine)

Target indication: Dementia associated with Lewy Bodies and Parkinson Disease

·      Preclinical study for NLS-12 (oxafuramine) shows positive results
for the treatment of neurological disorders including Dementia with Lewy
Bodies, Parkinson Disease and others using the novel object recognition (NOR)
test in mice models

·      NLS-12 specifically targets neurodegenerative diseases where
central muscarinic neurotransmission is compromised

·      The European Patent Office has granted approval for International
Patent Application No. PCT/EP2022/069200 including the NLS-12 mechanism of
action on muscarinic M4 and M5 receptors as agonist and its potential role on
the modulation of dopamine and its applications thereof for treating
neurodegenerative diseases with Lewy Body Disease and/or Alzheimer's Disease

R&D Day Webcast Information

The Company's R&D Day event will be held January 31, 2023, at 10:00 am EST
and will include a video stream on the Investors section of the Company's
website. A replay will be available on the NLS' website within 48 hours after
the event.

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage
biopharmaceutical company, working with a network of world-class partners and
internationally recognized scientists, focused on the discovery and
development of innovative therapies for patients with rare and complex central
nervous system, or CNS, disorders, who have unmet medical needs. Headquartered
in Switzerland and founded in 2015, NLS is led by an experienced management
team with a track record of developing and commercializing product candidates.
For more information, please visit www.nlspharma.com
(https://pr.report/pfkULmag) .

Safe Harbor Statement

This press release contains expressed or implied forward-looking statements
pursuant to U.S. Federal securities laws. For example, NLS is using
forward-looking statements when it discusses the potential benefits to be
derived from its product candidates, the inidications that its product
candidates may address and the potential for non-dilutive revenue. These
forward-looking statements and their implications are based on the current
expectations of the management of NLS only and are subject to a number of
factors and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. The following factors,
among others, could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology and market
requirements; NLS may encounter delays or obstacles in launching and/or
successfully completing its clinical trials; NLS' products may not be approved
by regulatory agencies, NLS' technology may not be validated as it progresses
further and its methods may not be accepted by the scientific community; NLS
may be unable to retain or attract key employees whose knowledge is essential
to the development of its products; unforeseen scientific difficulties may
develop with NLS' process; NLS' products may wind up being more expensive than
it anticipates; results in the laboratory may not translate to equally good
results in real clinical settings; results of preclinical studies may not
correlate with the results of human clinical trials; NLS' patents may not be
sufficient; NLS' products may harm recipients; changes in legislation may
adversely impact NLS; inability to timely develop and introduce new
technologies, products and applications; and loss of market share and pressure
on pricing resulting from competition, which could cause the actual results or
performance of NLS to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, NLS
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting NLS is contained under
the heading "Risk Factors" in NLS' annual report on Form 20-F for the year
ended December 31, 2021 filed with the Securities and Exchange Commission
(SEC), which is available on the SEC's website, www.sec.gov, and in subsequent
filings made by NLS with the SEC.

For additional information:

Marianne Lambertson (investors & media)

NLS Pharmaceutics Ltd.

+1 239.682.8500
ml@nls-pharma.com (mailto:ml@nls-pharma.com)
www.nlspharma.com (https://pr.report/yz9HZn0Y)

SOURCE: NLS Pharmaceutics Ltd.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABTMJTMTIBBLJ